190 results on '"de Souza, Mark S."'
Search Results
2. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
3. Pattern and Frequency of Seroreactivity to Routinely Used Serologic Tests in Early-Treated Infants With HIV
4. Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology
5. Transmission dynamics among participants initiating anti-retroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand
6. Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in Bangkok
7. Transmission dynamics among participants initiating antiretroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand
8. United States Department of Defense HIV-1 Vaccine Development in Thailand
9. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand
10. Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E
11. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
12. A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-Uninfected East Africans (RV 172)
13. Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection
14. Immune Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
15. Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand
16. Estimating HIV-1 incidence in Japan from the proportion of recent infections
17. Lymphoproliferative responses to HIV-1 Gag p24 antigen and mitogens in HIV-1 subtype CRF01_AE infected Thai patients and HIV-1 seronegative donors
18. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
19. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus erotype 5 boost vaccine in HIV-uninfected east Africans (RV 172)
20. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I /II ALVAC-HIV /AIDSVAX ® B/E prime-boost HIV-1 vaccine trial in Thailand
21. Preferential and persistent impact of acute HIV-1 infection on CD4+ iNKT cells in colonic mucosa.
22. Frequency of HIV false positivity from two sequential enzyme immunoassays in 111639 sera
23. Short Communication: Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders
24. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
25. A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity
26. Monoclonal Antibody to the Receptor for Murine Coronavirus MHV-A59 Inhibits Viral Replication in vivo
27. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
28. Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology
29. Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations
30. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
31. Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
32. Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines
33. Molecular Evolution of the HIV-1 Thai Epidemic between the Time of RV144 Immunogen Selection to the Execution of the Vaccine Efficacy Trial
34. IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.
35. HIV-1 Envelope Resistance to Proteasomal Cleavage: Implications for Vaccine Induced Immune Responses
36. Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E
37. HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E
38. Human Immunodeficiency Virus Type 1 Infection Is Associated with Increased NK Cell Polyfunctionality and Higher Levels of KIR3DL1 + NK Cells in Ugandans Carrying the HLA-B Bw4 Motif
39. Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans
40. Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
41. Quality Monitoring of HIV-1-Infected and Uninfected Peripheral Blood Mononuclear Cell Samples in a Resource-Limited Setting
42. Elevated Natural Killer Cell Activity Despite Altered Functional and Phenotypic Profile in Ugandans With HIV-1 Clade A or Clade D Infection
43. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans
44. Reference Intervals in Healthy Adult Ugandan Blood Donors and Their Impact on Conducting International Vaccine Trials
45. Reference Ranges for the Clinical Laboratory Derived from a Rural Population in Kericho, Kenya
46. Large-Scale Human Immunodeficiency Virus Rapid Test Evaluation in a Low-Prevalence Ugandan Blood Bank Population
47. A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine
48. Distinguishing molecular forms of HIV-1 in Asia with a high-throughput, fluorescent genotyping assay, MHAbce v.2
49. Lymphoproliferative responses to HIV-1 Gag p24 antigen and mitogens in HIV-1 subtype CRF01_AE infected Thai patients and HIV-1 seronegative donors
50. Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.